Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Is There a Preferred Infusional Regimen for Patients with Relapsed/Refractory Multiple Myeloma?

Patrick T. Griffin, MD, Viet Q. Ho, PharmD, BCOP, William Fulp, Taiga Nishihori, MD, Kenneth H. Shain, MD PhD, Melissa Alsina, MD, Rachid Baz, MD

Blood (2014) 124 (21): 4757.

https://doi.org/10.1182/blood.V124.21.4757.4757

Published: 2014

Journal Articles

A Comparison Of Acute Myelogenous Leukemia Induction Therapies: High Dose Daunorubicin Vs Idarubicin

Viet Q. Ho, PharmD, BCOP, Robert Cade, PharmD, Gene A. Wetzstein, PharmD, BCOP, Van D Hoang, PharmD, BCOP, Alan List, MD, Eric Padron, MD, Hugo F Fernandez, MD, Jeffrey E Lancet, MD, Rami S Komrokji, MD

Blood (2013) 122 (21): 3951.

https://doi.org/10.1182/blood.V122.21.3951.3951

Published: 2013

Journal Articles

Outcome of Patients with Lower-Risk Myelodysplastic Syndrome (MDS) After Azacitidine (AZA) Treatment Failure.

Asmita Mishra, MD, Jeffrey E Lancet, MD, Najla H Al Ali, Eric Padron, MD, Viet Q. Ho, PharmD, BCOP, Bryan J Little, Javier Pinilla-Ibarz, MD, PhD, Alan F. List, MD, Rami S. Komrokji, MD

Blood (2012) 120 (21): 2815.

https://doi.org/10.1182/blood.V120.21.2815.2815

Published: 2012

Journal Articles

Evidence for Selective Benefit of Sequential Treatment with Azanucleosides in Patients with Myelodysplastic Syndromes (MDS)

Susmitha Apuri, MD, Jeffrey E Lancet, MD, Najla H Al Ali, Eric Padron, MD, Viet Q. Ho, PharmD, BCOP, Javier Pinilla-Ibarz, MD, PhD, Alan F. List, MD, Rami S. Komrokji, MD

Blood (2012) 120 (21): 4937.

https://doi.org/10.1182/blood.V120.21.4937.4937

Published: 2012

Journal Articles

Efficacy of Ofatumumab and High-Dose Methylprednisolone for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Melissa L. Teichman, PharmD, BCOP, Viet Q. Ho, PharmD, BCOP, Lodovico Balducci, MD, Celeste M. Bello, MD, Javier Pinilla-Ibarz, M.D., Ph.D.

Blood (2011) 118 (21): 4619.

https://doi.org/10.1182/blood.V118.21.4619.4619

Published: 2011

Journal Articles

Bendamustine and Rituximab for the Treatment of Chronic Lymphocytic Leukemia: The Moffitt Cancer Center Experience

Heather Barnes Pound, PharmD, BCPS, Viet Q. Ho, PharmD, BCOP, Celeste M. Bello, MD, Jennifer L. Cultrera, MD, Martine Extermann, MD, PhD, Jeffrey E. Lancet, MD, Eduardo M. Sotomayor, Javier Pinilla-Ibarz, MD, PhD

Blood (2011) 118 (21): 4620.

https://doi.org/10.1182/blood.V118.21.4620.4620

Published: 2011

Journal Articles

Sequence of Therapy in Multiple Myeloma: Does It Matter? Retrospective Evaluation of Patients with Multiple Myeloma Who Have Received Bortezomib Followed by Lenalidomide or Vice Versa,

Amila M Patel, PharmD, Viet Q. Ho, PharmD, BCOP, Kenneth H. Shain, MD, PhD, Daniel Sullivan, MD, Melissa Alsina, MD, Leonel Ochoa, Taiga Nishihori, MD, Benjamin Djulbegovic, MD, PhD, William Dalton, PhD, MD, Rachid Baz, MD

Blood (2011) 118 (21): 3979.

https://doi.org/10.1182/blood.V118.21.3979.3979

Published: 2011

Journal Articles

Alternative Dosing of Cyclophosphamide, Bortezomib and Corticosteroids (CyBorD) for Relapsed/Refractory Multiple Myeloma

Viet Q. Ho, PharmD, BCOP, Elizabeth Finley-Oliver, RN, Kenneth H. Shain, MD, PhD, Melissa Alsina, MD, Leonel Ochoa, Taiga Nishihori, MD, Benjamin Djulbegovic, MD, PhD, Rachid Baz, MD

Blood (2011) 118 (21): 5142.

https://doi.org/10.1182/blood.V118.21.5142.5142

Published: 2011

Journal Articles

Rapid Infusion Rituximab in Maintenance Therapy: Is It Feasible?

Jolly R Patel, PharmD, Viet Q. Ho, PharmD, BCOP, Melissa L. Teichman, PharmD, BCOP, Lubomir Sokol, MD, PhD, Celeste M. Bello, MD, Jennifer L. Cultrera, MD, Eduardo M. Sotomayor, Gene A. Wetzstein, PharmD, BCOP

Blood (2011) 118 (21): 4973.

https://doi.org/10.1182/blood.V118.21.4973.4973

Published: 2011

Journal Articles

Outcomes Analysis of Doublets of Novel Agents with Corticosteroids Versus Regimens with 3 or More Agents for Multiple Myeloma (MM): A Retrospective Analysis

Rachid Baz, MD, Amila M Patel, PharmD, Viet Q. Ho, PharmD, BCOP, Kenneth Shain, MD, PhD, Melissa Alsina, MD, Taiga Nishihori, MD, Jose Leonel Ochoa-Bayona, M.D., Daniel Sullivan, MD, Benjamin Djulbegovic, MD, PhD, William S. Dalton, PhD, MD

Blood (2011) 118 (21): 1878.

https://doi.org/10.1182/blood.V118.21.1878.1878

Published: 2011

Journal Articles

A Retrospective Study of Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia: Lack of Response Observed In a Heavily Pretreated Population

Timothy J George, PharmD, BCOP, Joseph E Woolery, PharmD, Gene A. Wetzstein, PharmD, BCOP, Viet Q. Ho, PharmD, BCOP, Jeffrey E. Lancet, MD, Alan F. List, Rami S. Komrokji, MD

Blood (2010) 116 (21): 2186.

https://doi.org/10.1182/blood.V116.21.2186.2186

Published: 2010

Journal Articles

Efficacy of Azacitidine In the Treatment of Chronic Myelomonocytic Leukemia

Melissa L. Teichman, PharmD, Gene A. Wetzstein, PharmD, BCOP, Viet Q. Ho, PharmD, BCOP, Jeffrey E. Lancet, MD, Alan F. List, Rami S. Komrokji, MD

Blood (2010) 116 (21): 4017.

https://doi.org/10.1182/blood.V116.21.4017.4017

Published: 2010

Journal Articles

Optimizing Premedications In the Prevention of Bendamustine Infusion Related Reactions

Rebecca Tombleson, Viet Q. Ho, PharmD, BCOP, Eduardo M. Sotomayor, MD, Celeste M. Bello, MD, Jennifer L. Cultrera, MD, Javier Pinilla-Ibarz, MD, Lubomir Sokol, MD, PhD, Gene A. Wetzstein, PharmD, BCOP

Blood (2010) 116 (21): 4370.

https://doi.org/10.1182/blood.V116.21.4370.4370

Published: 2010

Journal Articles

Comparable Efficacy and Safety with Voriconazole or Posaconazole as Primary Antifungal Prophylaxis in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy.

Gene A Wetzstein, PharmD, BCOP, Timothy J. George, PharmD, BCOP, Mahsa Sharifi, PharmD, Van D Hoang, PharmD, BCOP, Viet Q Ho, PharmD, BCOP, Rod E Quilitz, PharmD, BCOP, Dana A Spears, PharmD, BCOP, Rami S. Komrokji, MD, Alan F List, MD, Jeffrey E Lancet, MD, John N Greene, MD

Blood (2009) 114 (22): 2059.

https://doi.org/10.1182/blood.V114.22.2059.2059

Published: 2009

Journal Articles

Safety, Feasibility, and Cost-Effectiveness with Outpatient Administration of High-Dose Cytarabine Consolidation in Acute Myeloid Leukemia

Gene A. Wetzstein, PharmD, BCOP, Jeffrey E. Lancet, MD, Jennifer E. Kallner, PharmD, Jeffrey M. Sivik, PharmD, BCOP, Viet Q. Ho, PharmD, BCOP, Timothy J. George, PharmD, BCOP, Sheetal Desai, PharmD, BCOP, Shanel Fisher, PharmD, Michael D. Newton, PharmD, BCOP, Alan F. List, MD

Blood (2008) 112 (11): 2405.

https://doi.org/10.1182/blood.V112.11.2405.2405

Published: 2008

NARROW

Is There a Preferred Infusional Regimen for Patients with Relapsed/Refractory Multiple Myeloma?

A Comparison Of Acute Myelogenous Leukemia Induction Therapies: High Dose Daunorubicin Vs Idarubicin

Outcome of Patients with Lower-Risk Myelodysplastic Syndrome (MDS) After Azacitidine (AZA) Treatment Failure.

Evidence for Selective Benefit of Sequential Treatment with Azanucleosides in Patients with Myelodysplastic Syndromes (MDS)

Efficacy of Ofatumumab and High-Dose Methylprednisolone for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Bendamustine and Rituximab for the Treatment of Chronic Lymphocytic Leukemia: The Moffitt Cancer Center Experience

Sequence of Therapy in Multiple Myeloma: Does It Matter? Retrospective Evaluation of Patients with Multiple Myeloma Who Have Received Bortezomib Followed by Lenalidomide or Vice Versa,

Alternative Dosing of Cyclophosphamide, Bortezomib and Corticosteroids (CyBorD) for Relapsed/Refractory Multiple Myeloma

Rapid Infusion Rituximab in Maintenance Therapy: Is It Feasible?

Outcomes Analysis of Doublets of Novel Agents with Corticosteroids Versus Regimens with 3 or More Agents for Multiple Myeloma (MM): A Retrospective Analysis

A Retrospective Study of Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia: Lack of Response Observed In a Heavily Pretreated Population

Efficacy of Azacitidine In the Treatment of Chronic Myelomonocytic Leukemia

Optimizing Premedications In the Prevention of Bendamustine Infusion Related Reactions

Comparable Efficacy and Safety with Voriconazole or Posaconazole as Primary Antifungal Prophylaxis in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy.

Safety, Feasibility, and Cost-Effectiveness with Outpatient Administration of High-Dose Cytarabine Consolidation in Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only